US 12,454,568 B2
Monoclonal antibody 2G1 for broad-spectrum neutralization of ebola viruses and application thereof
Wei Chen, Beijing (CN); Changming Yu, Beijing (CN); Pengfei Fan, Beijing (CN); Xiangyang Chi, Beijing (CN); Guanying Zhang, Beijing (CN); Jianmin Li, Beijing (CN); Lihua Hou, Beijing (CN); Junjie Xu, Beijing (CN); Ting Fang, Beijing (CN); Shipo Wu, Beijing (CN); Yi Chen, Beijing (CN); Zhengshan Chen, Beijing (CN); Yujiao Liu, Beijing (CN); and Meirong Wang, Beijing (CN)
Assigned to Academy of Military Medical Science, PLA, Bejing (CN)
Appl. No. 17/272,443
Filed by ACADEMY OF MILITARY MEDICAL SCIENCE, PLA, Beijing (CN)
PCT Filed May 10, 2019, PCT No. PCT/CN2019/086336
§ 371(c)(1), (2) Date Aug. 12, 2021,
PCT Pub. No. WO2020/093672, PCT Pub. Date May 14, 2020.
Claims priority of application No. 201811309856.1 (CN), filed on Nov. 6, 2018.
Prior Publication US 2024/0254201 A1, Aug. 1, 2024
Int. Cl. C07K 16/10 (2006.01); A61K 35/17 (2025.01); A61P 31/14 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/10 (2013.01) [A61K 35/17 (2013.01); A61P 31/14 (2018.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 10 Claims
 
1. An isolated monoclonal antibody that specifically binds to Ebola virus glycoprotein GP2 subunit, wherein the CDR1, CDR2 and CDR3 of light chain variable domain of the said antibody has the amino acid sequence as 27-32 of SEQ ID NO: 1, 50-52 of SEQ ID NO: 1 and 89-96 of SEQ ID NO: 1 respectively, the CDR1, CDR2 and CDR3 of heavy chain variable domain of the said antibody has the amino acid sequence as 26-33 of SEQ ID NO: 5, 51-58 of SEQ ID NO: 5 and 97-113 of SEQ ID NO: 5.